PMID- 26206648
OWN - NLM
STAT- MEDLINE
DCOM- 20151005
LR  - 20220318
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Print)
IS  - 1072-7515 (Linking)
VI  - 221
IP  - 2
DP  - 2015 Aug
TI  - Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple 
      Endocrine Neoplasia Type 1.
PG  - 509-17
LID - S1072-7515(15)00307-5 [pii]
LID - 10.1016/j.jamcollsurg.2015.04.005 [doi]
AB  - BACKGROUND: Screening for neuroendocrine tumors (NETs) in patients with multiple 
      endocrine neoplasia type 1 (MEN1) is recommended to detect primary and metastatic 
      tumors, which can result in significant morbidity and mortality. The utility of 
      somatostatin receptor imaging (68)Gallium-DOTATATE PET/CT in patients with MEN1 
      is not known. The aim of this study was to prospectively determine the accuracy 
      of (68)Gallium-DOTATATE PET/CT vs (111)In- pentetreotide single-photon emission 
      CT (SPECT)/CT and anatomic imaging in patients with MEN1. STUDY DESIGN: We 
      performed a prospective study comparing (68)Gallium-DOTATATE PET/CT, 
      (111)In-pentetreotide SPECT/CT, and triphasic CT scan to clinical, biochemical, 
      and pathologic data in 26 patients with MEN1. RESULTS: (68)Gallium-DOTATATE 
      PET/CT detected 107 lesions; (111)In-pentetreotide SPECT/CT detected 33 lesions; 
      and CT scan detected 48 lesions. Lesions detected on (68)Gallium-DOTATATE PET/CT 
      had high standard uptake value (SUV)(max) (median SUV(max) = 72.8 [range 19 to 
      191]). In 7 of the 26 patients (27%), (68)Gallium-DOTATATE PET/CT was positive, 
      with a negative (111)In-pentetreotide SPECT/CT, and in 10 patients (38.5%), 
      additional metastases were detected (range 0.3 cm to 1.5 cm). In 8 of the 26 
      patients (31%), there was a change in management recommendations as a result of 
      the findings on (68)Gallium-DOTATATE PET/CT that were not seen on 
      (111)In-pentetreotide SPECT/CT and CT scan. CONCLUSIONS: (68)Gallium-DOTATATE 
      PET/CT is more sensitive for detecting NETs than (111)In-pentetreotide SPECT/CT 
      and CT scan in patients with MEN1. This imaging technique should be integrated 
      into radiologic screening and surveillance of patients with MEN1 because it can 
      significantly alter management recommendations.
CI  - Published by Elsevier Inc.
FAU - Sadowski, Samira M
AU  - Sadowski SM
AD  - Endocrine Oncology Branch, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD. Electronic address: samira.sadowskiveuthey@nih.gov.
FAU - Millo, Corina
AU  - Millo C
AD  - Positron Emission Tomography Department, Warren Grant Magnusson Clinical Center, 
      National Institutes of Health, Bethesda, MD.
FAU - Cottle-Delisle, Candice
AU  - Cottle-Delisle C
AD  - Endocrine Oncology Branch, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD.
FAU - Merkel, Roxanne
AU  - Merkel R
AD  - Endocrine Oncology Branch, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD.
FAU - Yang, Lily A
AU  - Yang LA
AD  - Endocrine Oncology Branch, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD.
FAU - Herscovitch, Peter
AU  - Herscovitch P
AD  - Positron Emission Tomography Department, Warren Grant Magnusson Clinical Center, 
      National Institutes of Health, Bethesda, MD.
FAU - Pacak, Karel
AU  - Pacak K
AD  - Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National 
      Institute of Child Health & Human Development, National Institutes of Health, 
      Bethesda, MD.
FAU - Simonds, William F
AU  - Simonds WF
AD  - Metabolic Diseases Branch, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Bethesda, MD.
FAU - Marx, Stephen J
AU  - Marx SJ
AD  - Metabolic Diseases Branch, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Bethesda, MD.
FAU - Kebebew, Electron
AU  - Kebebew E
AD  - Endocrine Oncology Branch, National Cancer Institute, National Institutes of 
      Health, Bethesda, MD.
LA  - eng
GR  - Z99 CA999999/Intramural NIH HHS/United States
GR  - 1 ZIA BC011286 05/BC/NCI NIH HHS/United States
GR  - 1 ZIA BC011275 05/BC/NCI NIH HHS/United States
GR  - 1 ZID BC011534 01/BC/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20150420
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
RN  - 0 (Organometallic Compounds)
RN  - 0 (Radiopharmaceuticals)
RN  - 51110-01-1 (Somatostatin)
RN  - 9L17Y0H71P (gallium Ga 68 dotatate)
RN  - G083B71P98 (pentetreotide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*diagnostic imaging
MH  - *Organometallic Compounds
MH  - Positron-Emission Tomography/*methods
MH  - Prospective Studies
MH  - *Radiopharmaceuticals
MH  - Sensitivity and Specificity
MH  - Somatostatin/*analogs & derivatives
MH  - *Tomography, X-Ray Computed
PMC - PMC4515773
MID - NIHMS683349
EDAT- 2015/07/25 06:00
MHDA- 2015/10/06 06:00
PMCR- 2016/08/01
CRDT- 2015/07/25 06:00
PHST- 2015/01/15 00:00 [received]
PHST- 2015/03/11 00:00 [revised]
PHST- 2015/04/13 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2015/10/06 06:00 [medline]
PHST- 2016/08/01 00:00 [pmc-release]
AID - S1072-7515(15)00307-5 [pii]
AID - 10.1016/j.jamcollsurg.2015.04.005 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2015 Aug;221(2):509-17. doi: 10.1016/j.jamcollsurg.2015.04.005. 
      Epub 2015 Apr 20.